383 related articles for article (PubMed ID: 29477102)
41. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
[TBL] [Abstract][Full Text] [Related]
42. Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma.
Fischer L; Korfel A; Kiewe P; Neumann M; Jahnke K; Thiel E
Ann Hematol; 2009 Feb; 88(2):133-9. PubMed ID: 18679681
[TBL] [Abstract][Full Text] [Related]
43. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
44. Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project.
Bromberg JE; Doorduijn JK; Illerhaus G; Jahnke K; Korfel A; Fischer L; Fritsch K; Kuittinen O; Issa S; van Montfort C; van den Bent MJ
Haematologica; 2013 May; 98(5):808-13. PubMed ID: 23144196
[TBL] [Abstract][Full Text] [Related]
45. Central nervous system involvement in diffuse large B-cell lymphoma.
Yamamoto W; Tomita N; Watanabe R; Hattori Y; Nakajima Y; Hyo R; Hashimoto C; Motomura S; Ishigatsubo Y
Eur J Haematol; 2010 Jul; 85(1):6-10. PubMed ID: 20236301
[TBL] [Abstract][Full Text] [Related]
46. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
Patel MP; Kirkpatrick JP; Johnson MO; Healy P; Herndon JE; Lipp ES; Miller ES; Desjardins A; Randazzo D; Friedman HS; Ashley DM; Peters KB
J Neurooncol; 2020 Apr; 147(2):477-483. PubMed ID: 32140975
[TBL] [Abstract][Full Text] [Related]
47. [Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
Shimada K
Brain Nerve; 2011 May; 63(5):467-72. PubMed ID: 21515926
[TBL] [Abstract][Full Text] [Related]
48. Treatment Strategies and Prognostic Factors of Primary Gastric Diffuse Large B Cell Lymphoma: A Retrospective Multicenter Study of 272 Cases from the China Lymphoma Patient Registry.
Yang H; Wu M; Shen Y; Lei T; Mi L; Leng X; Ping L; Xie Y; Song Y; Cen X; Zhu J
Int J Med Sci; 2019; 16(7):1023-1031. PubMed ID: 31341416
[No Abstract] [Full Text] [Related]
49. Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study.
Fleury I; Amorim S; Mounier N; Coiffier B; Dupuis J; Tilly H; Mazari MA; Filliatre L; Brière J; Brice P; de Kerviler E; Thieblemont C
Leuk Lymphoma; 2015 Jul; 56(7):2025-31. PubMed ID: 25347431
[TBL] [Abstract][Full Text] [Related]
50. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
Doorduijn JK; van Imhoff GW; van der Holt B; Schouten HC; Schaafsma MR; MacKenzie MA; Baars JW; Kersten MJ; Lugtenburg PJ; van den Bent MJ; Enting RH; Spoelstra FM; Poortmans P; Bromberg JEC
Hematol Oncol; 2017 Dec; 35(4):497-503. PubMed ID: 27530779
[TBL] [Abstract][Full Text] [Related]
51. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
52. Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients.
Shimada K; Murase T; Matsue K; Okamoto M; Ichikawa N; Tsukamoto N; Niitsu N; Miwa H; Asaoku H; Kosugi H; Kikuchi A; Matsumoto M; Saburi Y; Masaki Y; Yamamoto K; Yamaguchi M; Nakamura S; Naoe T; Kinoshita T;
Cancer Sci; 2010 Jun; 101(6):1480-6. PubMed ID: 20412122
[TBL] [Abstract][Full Text] [Related]
53. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
[TBL] [Abstract][Full Text] [Related]
54. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Zhang J; Chen B; Xu X
Leuk Lymphoma; 2014 Mar; 55(3):509-14. PubMed ID: 23741977
[TBL] [Abstract][Full Text] [Related]
55. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
Strüßmann T; Fritsch K; Baumgarten A; Fietz T; Engelhardt M; Mertelsmann R; Ihorst G; Duyster J; Finke J; Marks R
Br J Haematol; 2017 Sep; 178(6):927-935. PubMed ID: 28643323
[TBL] [Abstract][Full Text] [Related]
56. Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.
Berlanga P; Pasqualini C; Pötschger U; Sangüesa C; Castellani MR; Cañete A; Luksch R; Elliot M; Schreier G; Kropf M; Morgenstern D; Papadakis V; Ash S; Ruud E; Brock P; Wieczorek A; Kogner P; Trahair T; Ambros P; Boterberg T; Castel V; Valteau-Couanet D; Ladenstein R
Eur J Cancer; 2021 Feb; 144():1-8. PubMed ID: 33316634
[TBL] [Abstract][Full Text] [Related]
57. Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high-dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis.
Bennett R; Ruskova A; Coomarasamy C; Theakston E; Berkahn L; Jackson S; Christophers M; Wong S; Issa S
Am J Hematol; 2023 Jul; 98(7):1070-1079. PubMed ID: 37161765
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B‑cell lymphoma with secondary central nervous system involvement.
Lee MY; Kim HS; Lee JY; Lim SH; Kang ES; Ko YH; Kim SJ; Kim WS
Int J Hematol; 2015 Dec; 102(6):678-88. PubMed ID: 26493833
[TBL] [Abstract][Full Text] [Related]
59. Ranimustine, ifosfamide, procarbazine, dexamethasone, and etoposide therapy for central nervous system recurrence of diffuse large B-cell lymphoma in patients with poor performance status: a pilot study.
Miwa A; Sekiguchi N; Tanimura A; Homma C; Shikai T; Takezako Y; Yamagata N; Takezako N
Leuk Lymphoma; 2011 Oct; 52(10):1898-903. PubMed ID: 21649542
[TBL] [Abstract][Full Text] [Related]
60. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B-cell lymphoma in the rituximab era.
Vassilakopoulos TP; Panitsas F; Mellios Z; Apostolidis J; Michael M; Gurion R; Ferhanoglu B; Hatzimichael E; Karakatsanis S; Dimou M; Kalpadakis C; Katodritou E; Leonidopoulou T; Kotsianidis I; Giatra H; Kanellias N; Sayyed A; Tadmor T; Akay OM; Angelopoulou MK; Horowitz N; Bakiri M; Pangalis GA; Panayiotidis P; Papageorgiou SG
Hematol Oncol; 2023 Feb; 41(1):97-107. PubMed ID: 36314897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
